- Trials with a EudraCT protocol (26)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
26 result(s) found for: Nutrition Disorders AND Weight Loss AND Obesity.
Displaying page 1 of 2.
| EudraCT Number: 2019-002274-31 | Sponsor Protocol Number: U1111-1215-8606 | Start Date*: 2020-12-16 | |||||||||||
| Sponsor Name:Department of Biomedical Sciences, University of Copenhagen | |||||||||||||
| Full Title: Young adults with early-onset obesity treated with semaglutide | |||||||||||||
| Medical condition: Obesity | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-002755-42 | Sponsor Protocol Number: 1069/12 | Start Date*: 2012-11-06 | |||||||||||
| Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
| Full Title: OBESITY AND ASPIRIN RESPONSIVENESS | |||||||||||||
| Medical condition: OBESITY | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-001540-38 | Sponsor Protocol Number: NN9536-4153 | Start Date*: 2015-08-24 | |||||||||||
| Sponsor Name:Novo Nordisk A/S | |||||||||||||
| Full Title: Investigation of safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus. A 52-week, randomised, double-blind, placebo-controlled, nine-armed, parallel group, mul... | |||||||||||||
| Medical condition: Obesity | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) DE (Completed) GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-004353-14 | Sponsor Protocol Number: NN8022-4180 | Start Date*: 2016-08-15 | |||||||||||
| Sponsor Name:Novo Nordisk A/S | |||||||||||||
| Full Title: Effect of liraglutide for weight management in pubertal adolescent subjects with obesity. 56-week, double-blind, randomised, parallel-group, placebo-controlled multi-national trial followed by a 26... | |||||||||||||
| Medical condition: Obesity | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-016921-32 | Sponsor Protocol Number: HSJD-OB-TRP | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:Fundació Sant Joan de Déu | |||||||||||||
| Full Title: A phase II, randomized, double-blind, placebo-controlled, in parallel groups clinical trial to assess the safety and efficacy of dietary supplementation with tryptophan to achieve weight loss, and ... | |||||||||||||
| Medical condition: obesity | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-002479-37 | Sponsor Protocol Number: 1404-0036 | Start Date*: 2021-03-15 | |||||||||||
| Sponsor Name:Boehringer Ingelheim AB | |||||||||||||
| Full Title: A Phase II, randomized, double blind, parallel group,46 weeks dose-finding study of BI 456906 administered once weekly subcutaneously compared with placebo in patients with obesity or overweight | |||||||||||||
| Medical condition: obesity | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) IE (Prematurely Ended) NL (Completed) BE (Completed) DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-001049-24 | Sponsor Protocol Number: NN8022-1839 | Start Date*: 2008-12-02 | ||||||||||||||||
| Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||
| Full Title: Effect of liraglutide on body weight in non-diabetic obese subjects or overweight subjects with comorbidities A randomised, double-blind, placebo controlled, parallel group, multi-centre, multina... | ||||||||||||||||||
| Medical condition: Obesity and overweight Pre-diabetes | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IE (Completed) FI (Completed) ES (Completed) DE (Completed) DK (Completed) AT (Completed) GB (Completed) FR (Completed) IT (Completed) NL (Completed) BE (Completed) PL (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2015-005619-33 | Sponsor Protocol Number: NN8022-4272 | Start Date*: 2016-12-14 | |||||||||||
| Sponsor Name:Novo Nordisk A/S | |||||||||||||
| Full Title: Effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin | |||||||||||||
| Medical condition: Obesity | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-005585-32 | Sponsor Protocol Number: 111111733104 | Start Date*: 2016-06-24 | |||||||||||
| Sponsor Name:Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen | |||||||||||||
| Full Title: Synergy effect of the appetite hormone GLP-1 (LiragluTide) and Exercise on maintenance of weight loss and health after a low calorie diet - the S-LiTE randomized trial | |||||||||||||
| Medical condition: Obesity | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-003616-39 | Sponsor Protocol Number: 64565111OBE2001 | Start Date*: 2018-04-27 | |||||||||||
| Sponsor Name:Janssen-Cilag International NV | |||||||||||||
| Full Title: A Randomized, Double-blind Placebo-controlled and Open-label Active-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic S... | |||||||||||||
| Medical condition: Obesity | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) BE (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-004415-37 | Sponsor Protocol Number: NN8022-4179 | Start Date*: 2015-11-10 | |||||||||||
| Sponsor Name:Novo Nordisk A/S | |||||||||||||
| Full Title: Effect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome. A randomised, placebo controlled, parallel group, multi-centre, multinational trial with a 16-week dou... | |||||||||||||
| Medical condition: Obesity (Prader-Willi syndrome) | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) FR (Completed) NL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-002470-86 | Sponsor Protocol Number: 20190218 | Start Date*: 2023-05-08 | ||||||||||||||||
| Sponsor Name:Amgen Inc. | ||||||||||||||||||
| Full Title: A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without... | ||||||||||||||||||
| Medical condition: Overweight and Obesity | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2017-002407-10 | Sponsor Protocol Number: 17/0238 | Start Date*: 2018-03-23 | ||||||||||||||||
| Sponsor Name:University College London | ||||||||||||||||||
| Full Title: A double-blinded, randomised, placebo-controlled trial of liraglutide 3.0 mg in patients with poor weight-loss and a suboptimal glucagon-like peptide-1 response following bariatric surgery. | ||||||||||||||||||
| Medical condition: Obesity. | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2008-002199-88 | Sponsor Protocol Number: NN8022-1922 | Start Date*: 2008-12-15 | ||||||||||||||||
| Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||
| Full Title: Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes A 56 week randomised, double-blind, placebocontrolled, three armed parallel group, multi-centre, multina... | ||||||||||||||||||
| Medical condition: Obesity and overweight | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) SE (Completed) ES (Completed) FR (Completed) GB (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2016-002868-14 | Sponsor Protocol Number: CLIK066B2201 | Start Date*: 2017-04-18 | ||||||||||||||||
| Sponsor Name:Novartis Pharma AG | ||||||||||||||||||
| Full Title: A randomized, double-blind, dose-finding study to evaluate the change in weight after 24 weeks treatment with 8 doses of LIK066 compared to placebo in obese or overweight adults, followed by 24 wee... | ||||||||||||||||||
| Medical condition: change in weight in obese or overweight adults | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: SK (Completed) CZ (Completed) AT (Completed) HU (Completed) GB (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2020-005989-34 | Sponsor Protocol Number: 034B20 | Start Date*: 2022-08-31 | |||||||||||
| Sponsor Name:Aphaia Pharma AG | |||||||||||||
| Full Title: A Phase II, randomized, double-blind, placebo-controlled, parallel-group proof-of-concept study to evaluate efficacy and safety of distal jejunal-release dextrose (Aphaia technology, AT) in obese s... | |||||||||||||
| Medical condition: Obesity with/without associated endocrine and/or metabolic conditions and/or hypertension and/or NASH and/or NAFL with/without fibrosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-002314-39 | Sponsor Protocol Number: Semaglutide2019 | Start Date*: 2021-07-08 | ||||||||||||||||
| Sponsor Name:University College Dublin (UCD) | ||||||||||||||||||
| Full Title: A randomised, controlled, parallel group, open-label trial evaluating the impact of treatment with the GLP-1 analogue semaglutide on weight loss in people living with HIV and obesity | ||||||||||||||||||
| Medical condition: Human immunodeficiency virus (HIV) Infection and Obesity | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IE (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2019-004545-32 | Sponsor Protocol Number: EP-002 | Start Date*: 2020-04-16 | |||||||||||
| Sponsor Name:Empros Pharma AB | |||||||||||||
| Full Title: Lean Efficacy Phase IIa Proof of concept trial (LEAAP). A multi-centre, double-blind, placebo controlled, randomised study in overweight and obese patients during twenty-six weeks, investigating th... | |||||||||||||
| Medical condition: Obesity | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-001145-93 | Sponsor Protocol Number: 69HCL15_0057 | Start Date*: 2015-10-07 | ||||||||||||||||
| Sponsor Name:Hospices Civils de Lyon | ||||||||||||||||||
| Full Title: Étude pharmacocinétique de la lidocaïne par voie intraveineuse en chirurgie bariatrique - Etude SPIRAL (Safety Profile of IntRAvenous Lidocaïne use in coelioscopic bariatric surgery) | ||||||||||||||||||
| Medical condition: Obésité / Chirurgie bariatrique | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Ongoing) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2022-002834-15 | Sponsor Protocol Number: C3991004 | Start Date*: 2023-01-31 | ||||||||||||||||
| Sponsor Name:Pfizer Inc. | ||||||||||||||||||
| Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE RANGING, DOSE FINDING, PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF-07081532, AND OPEN LABEL ORAL SEMAGLUTIDE, IN ADULTS WI... | ||||||||||||||||||
| Medical condition: Type 2 Diabetes Mellitus and Obesity | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: CZ (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.